TY  - GEN
AU  - Stević, Ivana
AU  - Janković, Slobodan M
AU  - Petrović, Nemanja
AU  - Čanak-Baltić, Nataša
AU  - Lakić, Dragana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5623
AB  - Drug-induced disorder „can result from unanticipated or anticipated drug effects“ (1).
The prevalence of hematological adverse drug reactions (ADR) in chemotherapeutics is
expected to be high; for non-chemotherapeutics, there is insufficient epidemiological data,
although a spontaneous reporting system is mandatory in a drug's life cycle (2-6). ADR is
considered to be the fifth cause of death, with the hospitalization rate caused by ADR estimated
to be between 0.9-7.9% (7-8), while one study suggests that about „10 to 20% of hospitalized
patients will experience ADRs during their stay“ (9). Frequency data on hospital admissions
due to hematological ADR vary between studies, e.g., 9% (7) up to 26.5% (10).
The study by Abu et al. categorized major ADR types based on system disorders, where
hematologic ADR encountered 9.9-15.2% of ADRs (9). The same study estimated costs per
ADR from 65.00 to 12,129.90 USD, whereas costs were generally lower when the micro-
costing approach was used (9).
A cost-of-illness (COI) study should be performed to precisely determine the costs
generated by ADR. COI studies measure the economic burden of an illness on society, health
insurance funds, or patients. Jefferson et al. (2000) defined “the aim of COI studies is
descriptive: to itemize, value, and sum the costs of a particular problem with the aim of giving
an idea of its economic burden“ (11). There are different methods of conducting this type of
study, such as prevalence‐based, incidence‐based, or econometric approaches, with again
different approaches (e.g., prospective, retrospective; top-down, bottom-up…) or with different
perspectives of COI studies (such as societal, health care system, third-party payer) (11).
However, micro-costing studies represent the gold standard for conducting COI studies (12).
Only a few cost drivers of HADR have been proven to date, e.g., prolonged in-hospital stay,
costs of using drugs, and transfusion costs (13-14).
T1  - Non-oncological
drug-induced blood disorders: a cost of illness study using the
microcosting Methodology - study plan [protocol]
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5623
ER  - 

@misc{
author = "Stević, Ivana and Janković, Slobodan M and Petrović, Nemanja and Čanak-Baltić, Nataša and Lakić, Dragana",
year = "2022",
abstract = "Drug-induced disorder „can result from unanticipated or anticipated drug effects“ (1).
The prevalence of hematological adverse drug reactions (ADR) in chemotherapeutics is
expected to be high; for non-chemotherapeutics, there is insufficient epidemiological data,
although a spontaneous reporting system is mandatory in a drug's life cycle (2-6). ADR is
considered to be the fifth cause of death, with the hospitalization rate caused by ADR estimated
to be between 0.9-7.9% (7-8), while one study suggests that about „10 to 20% of hospitalized
patients will experience ADRs during their stay“ (9). Frequency data on hospital admissions
due to hematological ADR vary between studies, e.g., 9% (7) up to 26.5% (10).
The study by Abu et al. categorized major ADR types based on system disorders, where
hematologic ADR encountered 9.9-15.2% of ADRs (9). The same study estimated costs per
ADR from 65.00 to 12,129.90 USD, whereas costs were generally lower when the micro-
costing approach was used (9).
A cost-of-illness (COI) study should be performed to precisely determine the costs
generated by ADR. COI studies measure the economic burden of an illness on society, health
insurance funds, or patients. Jefferson et al. (2000) defined “the aim of COI studies is
descriptive: to itemize, value, and sum the costs of a particular problem with the aim of giving
an idea of its economic burden“ (11). There are different methods of conducting this type of
study, such as prevalence‐based, incidence‐based, or econometric approaches, with again
different approaches (e.g., prospective, retrospective; top-down, bottom-up…) or with different
perspectives of COI studies (such as societal, health care system, third-party payer) (11).
However, micro-costing studies represent the gold standard for conducting COI studies (12).
Only a few cost drivers of HADR have been proven to date, e.g., prolonged in-hospital stay,
costs of using drugs, and transfusion costs (13-14).",
title = "Non-oncological
drug-induced blood disorders: a cost of illness study using the
microcosting Methodology - study plan [protocol]",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5623"
}

Stević, I., Janković, S. M., Petrović, N., Čanak-Baltić, N.,& Lakić, D.. (2022). Non-oncological
drug-induced blood disorders: a cost of illness study using the
microcosting Methodology - study plan [protocol]. .
https://hdl.handle.net/21.15107/rcub_farfar_5623

Stević I, Janković SM, Petrović N, Čanak-Baltić N, Lakić D. Non-oncological
drug-induced blood disorders: a cost of illness study using the
microcosting Methodology - study plan [protocol]. 2022;.
https://hdl.handle.net/21.15107/rcub_farfar_5623 .

Stević, Ivana, Janković, Slobodan M, Petrović, Nemanja, Čanak-Baltić, Nataša, Lakić, Dragana, "Non-oncological
drug-induced blood disorders: a cost of illness study using the
microcosting Methodology - study plan [protocol]" (2022),
https://hdl.handle.net/21.15107/rcub_farfar_5623 .